On January 29, 2019, the Board of Directors (the “Board”) of Neos Therapeutics, Inc. (the “Company”) unanimously appointed James Robinson to fill the newly created vacancy on the Board resulting from an increase in the size of the Board from seven (7) directors to eight (8) directors. Upon his appointment to the Board, Mr. Robinson became a member of the class of directors with terms expiring at the 2019 Annual Meeting of Stockholders of the Company. The Board has determined that Mr. Robinson qualifies as an independent director and is qualified to serve under the applicable rules and regulations of the Securities and Exchange Commission (the “SEC”) and the listing rules of the Nasdaq Stock Market LLC. Mr. Robinson will serve as a member of the Company’s Compensation Committee. Mr. Robinson, age 49, has been the President and Chief Operating Officer at Alkermes, Inc. since March 2018. Prior to that, Mr. Robinson served as President, Americas Operations for Astellas US LLC (“Astellas”), from April 2016 through February 2018. From April 2013 until March 2016, Mr. Robinson served as President for Astellas Pharma US, which is responsible for Astellas’ commercial organization in the United States. In addition, Mr. Robinson served on the board of directors of Pharmaceutical Research and Manufacturers of America from 2013 to March 2018.